The distinct MOAs between anti-TIGIT antibodies (Figures 8A–E) and anti-PD-1/PD-L1 antibodies highlighted the potential of BGB-A1217 to be used in combination therapy with PD-1/PD-L1 blocking mAbs in cancer treatment and provided strong rationale for using wild-type IgG1 Fc as the optimal format. Here, CD274 is linked to cancer.